~~<i id='63F6B012E6'><strike id='63F6B012E6'><tt id='63F6B012E6'><pre id='63F6B012E6'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：comprehensive 2025-08-26 03:35:22 Page View：27757

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： AstraZeneca bets AAV gene therapy will still deliver the goods
Next article： Heart attack and stroke risk calculators need revising

focus

Guidelines to prevent youth baseball injuries need more muscle

Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

Delta passengers in Vegas fall sick while waiting on flight in triple

1:30InthisMarch4,2018,filephoto,aBoeing737jetliner,belongingtoDeltaAirlines,isshownonthetarmacMcCarr

Duchenne breakthrough therapy leaves behind pioneering families

DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

How Long Island became the ‘eugenics capital of the world’

Thestudyofeugenicswasn’tbornonLongIsland—it’sclosertosayitwentthroughpubertythere.Theideaofeugenics—